Spectrum of germline cancer susceptibility gene mutations in Turkish colorectal cancer patients: a single center study

Background/aim: Quarter of colorectal cancer patients have a family history and 6% of these comprise hereditary cancer syndromes.For developing national health strategies for genetic screening, it is crucial to determine the spectrum of damaging alterations incausative genes and to describe frequent founder mutations.Materials and methods: One hundred and thirty six unrelated colorectal cancer cases were investigated. Qiagen large hereditary cancerpanel and Hereditary Cancer Solution v1.1 panel were used for sequencing. The sequencing process was performed on the IlluminaMiSeq system. The data analyses were performed on QIAGEN Clinical Insight (QCI™) Analyze software and Sophia DDM software.Results: Of 136 patients, 11 (8%) were found to carry a pathogenic and 2 (1.4%) were found to carry a likely pathogenic mutation.Altogether, 12 different pathogenic and likely pathogenic mutations were detected.Conclusion: This study is the first study in Turkish colorectal cancer patients using next-generation sequencing. Point mutationscreening in the families of patients with mutations will be able to identify individuals at risk in a cost-effective manner.

PDF

___

1. Gültekin M, Boztaş G. Türkiye kanser istatistikleri. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu 2014; pp. 43 (in Turkish).
2. Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. Nature Reviews Gastroenterology & Hepatology 2015; 12 (2): 88.
3. Sinicrope FA. Lynch syndrome-associated colorectal cancer. New England Journal of Medicine 2018; 379 (8): 764-773.
4. Beiner ME, Rosen B, Fyles A, Harley I, Pal T et al. Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiology and Prevention Biomarkers 2006; 15 (9): 1636-1640.
5. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. The American Journal of Gastroenterology 2015; 110 (2): 223.
6. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66 (3): 589-600.
7. Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. The Journal of the American Medical Association 2012; 308 (5): 485-492.
8. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Critical Reviews in Oncology/Hematology 2011; 79 (1): 1-16.
9. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM et al. Increased risk of cancer in the Peutz– Jeghers syndrome. New England Journal of Medicine 1987; 316 (24): 1511-1514.
10. Calva‐Cerqueira D, Chinnathambi S, Pechman B, Bair J, Larsen‐Haidle J et al. The rate of germline mutations and large deletions of SMAD4 and BMPR1A in juvenile polyposis. Clinical Genetics 2009; 75 (1): 79-85.
11. Li J, Yen C, Liaw D, Podsypanina K, Bose S et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275 (5308): 1943-1947.
12. van Gool IC, Bosse T, Church DN. POLE proofreading mutation, immune response and prognosis in endometrial cancer. Oncoimmunology 2016; 5 (3): e1072675.
13. Rohlin A, Eiengård F, Lundstam U, Zagoras T, Nilsson S et al. GREM 1 and POLE variants in hereditary colorectal cancer syndromes. Genes, Chromosomes and Cancer 2016; 55 (1): 95-106.
14. LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genetics in Medicine 2019: 1-9.
15. Susswein LR, Marshall ML, Nusbaum R, Postula KJV, Weissman SM et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for nextgeneration cancer panel testing. Genetics in Medicine 2016; 18 (8): 823.
16. Jones N, Vogt S, Nielsen M, Christian D, Wark PA et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009; 137 (2): 489-494. e481.
17. Morak M, Laner A, Bacher U, Keiling C, Holinski‐Feder E. MUTYH‐associated polyposis–variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. Clinical Genetics 2010; 78 (4): 353-363.
18. Rouleau E, Zattara H, Lefol C, Noguchi T, Briaux A et al. First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome. Clinical Genetics 2011; 80 (3): 301-303.
19. Torrezan GT, da Silva FC, Krepischi AC, Santos ÉM, de O Ferreira F et al. Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: case report. BMC Medical Genetics 2011; 12 (1): 128.
20. Castillejo A, Vargas G, Castillejo MI, Navarro M, Barberá VM et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. European Journal of Cancer 2014; 50 (13): 2241-2250.
21. Ricci MT, Miccoli S, Turchetti D, Bondavalli D, Viel A et al. Type and frequency of MUTYH variants in Italian patients with suspected MAP: a retrospective multicenter study. Journal of Human Genetics 2017; 62 (2): 309.
22. Farrington SM, Tenesa A, Barnetson R, Wiltshire A, Prendergast J et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. The American Journal of Human Genetics 2005; 77 (1): 112-119.
23. Meijers-Heijboer H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. The American Journal of Human Genetics 2003; 72 (5): 1308-1314.
24. Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome–literature review. Hereditary Cancer in Clinical Practice 2013; 11 (1): 9.
25. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Medscape General Medicine 2005; 7 (2): 60.
26. Katona BW, Stadler ZK, Robson ME, Domchek SM. RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute 2019; 111 (5): 522-523.
27. Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM et al. Germline TP53 mutations in patients with early-onset colorectal cancer in the colon cancer family registry. JAMA oncology 2015; 1 (2): 214-221.
28. Consortium APG. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery 2017; 7 (8): 818-831.
29. Park DJ, Tao K, Le Calvez-Kelm F, Nguyen-Dumont T, Robinot N et al. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome–spectrum cancers. Cancer Discovery 2014; 4 (7): 804-815.